Advertisement Acura names new VP of modified release dosage form development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Acura names new VP of modified release dosage form development

Acura Pharmaceuticals has appointed Garth Boehm as its new vice president of modified release dosage form development.

Dr Boehm is currently employed as vice president of product development at Actavis Pharmaceuticals and is expected to commence employment with Acura in May 2009.

Andy Reddick, president and CEO of Acura, said: “We are delighted that Dr Boehm will be joining our talented research, development, and senior management teams. We look forward to working with Dr Boehm as we remain intensely focused on developing a broad array of proprietary products with unique abuse deterrent features and benefits.”